The shares of Johnson & Johnson (NYSE:JNJ) has performed poorly over the past three months, as it lost around -5.79% while it has so far retreated around -9.88% during the course of a year. It went up by $0.04 now trading at $129.75. Their shares witnessed a 9.38% increase from the 52-week low price of $118.62 they recorded on 2018-05-29. Even though it is still -14.83% behind the $148.99 high touched on 2018-12-04. The last few days have been good for the stock, as its price has grew by 1.5% during the week. The stock of JNJ recorded 0.54% uptrend from the beginning of this year till date. The 12-month potential price target for Johnson & Johnson is set at $146.39. This target means that the stock has an upside potential to increase by 12.82% from the current trading price.
When giving their opinion, around 50% of Wall Street analysts, which represents 9 out of 18 rated the stock as a Buy. 8 brokerage firms of the remaining 44.44% rated the stock as a Hold with 1 analyst rating it as a sell. Overall, the number of aggregate JNJ shares held by institutional investors represents 68.7% of total shares. 80 institutions entered new Johnson & Johnson (NYSE:JNJ) positions, 1170 added to their existing positions in these shares, 1180 lowered their positions, and 67 exited their positions entirely.
Johnson & Johnson (JNJ) trade volume has decreased by -49.41% as around 5,294,572 shares were sold when compared with its 50-day average volume of traded shares which is 10,466,654. At the moment, JNJ is witnessing a downtrend, as it is trading -0.26% below its 20-day SMA, -6.31% below its 50-day SMA, and -1.79% below its 200-day SMA. The company runs an ROE of roughly 2.5%, with financial analysts predicting that their earnings per share growth will be around 7.76% per annum for the next five year. This will be compared to the 6.2% increase witnessed over the past five years.
The first technical resistance point for Johnson & Johnson (NYSE:JNJ) will likely come at $130.29, marking a 0.41% premium to the current level. The second resistance point is at $130.83, about 0.83% premium to its current market price. On the other hand, inability to breach the immediate hurdles can drag it down to $127.77, the lower end of the range. JNJ’s 14-day MACD is 1.75 and this positive figure indicates an upward trading trend. The company’s 14-day RSI (relative strength index) score is 44.17, which shows that its stock has been neutral. The 20-day historical volatility for the stock stands at 44.97 percent, which is high when compared to that of the 50-day’s 31.79 percent.
The shares of Medtronic plc (NYSE:MDT) has decreased by 0%, and now trading at $84.84 on the Wall Street in the intra-day deal, with their shares traded now around 4,971,808. This is a decline of -1,409,000 shares over the average 6,380,808 shares that were traded daily over the last three months. The stock that is trading at $84.84 went higher by 11.03% from its 52-week low of $76.41 that it attained back on 2018-03-23. The stock recorded a 52-week high of $100.15 nearly 110 days ago on 2018-09-26..
MDT stock hasn’t performed well over the past 30 days, as it lost -11.13% while its price plunged by -6.73% year-to-date (YTD). Looking at the last few days, it has been tough for the stock, as it tumbled -3.73% over the last week. The stock’s 12-month potential target price is now at $103.56. This means that the stock price might likely increase by 22.07% from its current trading price.17 out of 29 Wall Street analysts which represents 58.62% rated the stock as a buy while the remaining 41.38 rated it as a hold, with 0 of analysts rating it as a sell.
Medtronic plc (NYSE:MDT) has been utilizing an ROE that is roughly 0%, with stock analysts predicting that the company’s EPS for the next five years will go up by 8.46% per year, following the 3.8% raise that was witnessed during the past five years. The stock at the moment is on a downtrend, trading -4.62% below its 20-day SMA, -7.4% below its 50-day SMA, and -5.16% below its 200-day SMA. In percentage terms, the aggregate Medtronic plc shares held by institutional investors is 84.5%. 136 institutions jumped in to acquire Medtronic plc (MDT) fresh stake, 664 added to their current holdings in these shares, 652 lowered their positions, and 57 left no stake in the company.
The stock’s 9-day MACD is -1.11 and this negative figure indicates a downward trading trend. The company’s 9-day RSI score is 39.92, which shows that its stock has been neutral. The 20-day historical volatility for the shares stand at 42.89 percent, which is more when compared to that of the 50-day’s 29.36 percent. On the daily chart, we see that the stock could reach the first level of resistance at $85.33, sporting a 0.57% premium to the current level. The next resistance point is at $85.82, representing nearly 1.14% premium to the current market price of Medtronic plc (MDT). On the other hand, failure to breach the immediate hurdles can drag it down to $82.96, the lower end of the range.